Search results for "Bleeding episodes"

showing 9 items of 9 documents

Treatment of severe von Willebrand disease with a high‐purity von Willebrand factor concentrate (Wilfactin®): a prospective study of 50 patients

2007

Background and objectives: A plasma-derived von Willebrand factor (VWF) concentrate with low factor VIII (FVIII) content was specifically developed to treat von Willebrand disease (VWD). Efficacy and safety were investigated by merging the results of two comparable protocols conducted prospectively in 5 European and 12 French centers. Methods and results: Fifty patients with clinically severe VWD (72% had VWF ristocetin cofactor activity less than 10 IU dL(-1) and 46% had FVIII < 20 IU dL(-1)) were treated with the concentrate as the only therapy, except for clinical situations requiring a priming dose of FVIII to rapidly correct an intrinsic coagulation defect. A total of 139 spontaneous b…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyAdolescentHemorrhagePostoperative HemorrhageGastroenterologyVon Willebrand factorhemic and lymphatic diseasesInternal medicinevon Willebrand FactormedicineVon Willebrand diseaseHumansProspective StudiesChildProspective cohort studyAgedAged 80 and overHemostasisBleeding episodesFactor VIIIbiologybusiness.industryHematologyMiddle Agedmedicine.diseaseSurgeryClinical trialvon Willebrand DiseasesCoagulationChild PreschoolHemostasisConcomitantbiology.proteinFemaleSafetybusinessJournal of Thrombosis and Haemostasis
researchProduct

Effect of radiosynoviorthesis on the progression of arthropathy and haemarthrosis reduction in haemophilic patients.

2017

IntroductionRepeated haemarthrosis is widely accepted as the triggering cause of synovitis and haemophilic arthropathy. A first-line treatment of chronic synovitis is radiosynoviorthesis (RS). The aim of this study was to evaluate the RS effects on the progression of arthropathy and on a reduction in bleeding in patients with haemophilia. MethodsAn observational-retrospective study was performed. Bleeding episodes in the 12months following and in the 12months preceding RS was compared. The arthropathy was clinically and radiologically analysed by age range, joint and subject, comparing those undergoing RS (Radiosynoviorthesis Group, RSG) against those not undergoing this treatment (Non-Radi…

Adultmedicine.medical_specialtyAdolescentmedicine.medical_treatment030204 cardiovascular system & hematologyHaemophiliaHemophilia AGastroenterologyradiosynoviorthesis03 medical and health sciencesYoung Adult0302 clinical medicinehaemarthrosisSynovectomyInternal medicineSynovitisArthropathyElbow JointHemarthrosismedicineHumansIn patientYttrium RadioisotopesGenetics (clinical)Reduction (orthopedic surgery)Retrospective StudiesRadioisotopesHaemophilic arthropathyBleeding episodesSynovitisbusiness.industryShoulder Jointhaemophilic arthropathyHematologyGeneral MedicineMiddle Agedmedicine.diseaseChronic synovitisRheniumTreatment OutcomeDisease ProgressionJoint DiseasesbusinesssynovitisAnkle Joint030215 immunologyHaemophilia : the official journal of the World Federation of Hemophilia
researchProduct

Oral Communication

2012

Inherited factor VII (FVII) deficiency is the most common of the rare autosomal recessive bleeding disorders (RBD), with an estimated prevalence of 1 per 300,000 in European countries.1,2 It is likely that the prevalence is higher in those countries where consanguineous marriages are frequent.We here report STER study results on 112 evaluable enrolled cases

Inherited Factor VII deficiency prophylaxisspontaneous bleeding episodesSettore MED/15 - Malattie Del Sangue
researchProduct

Replacement therapy for bleeding episodes in factor VII deficiency: A prospective evaluation

2013

Patients with inherited factor VII (FVII) deficiency display different clinical phenotypes requiring ad hoc management. This study evaluated treatments for spontaneous and traumatic bleeding using data from the Seven Treatment Evaluation Registry (STER). One-hundred one bleeds were analysed in 75 patients (41 females; FVII coagulant activity <1-20%). Bleeds were grouped as haemarthroses (n=30), muscle/subcutaneous haematomas (n=16), epistaxis (n=12), gum bleeding (n=13), menorrhagia (n=16), central nervous system (CNS; n=9), gastrointestinal (GI; n=2) and other (n=3). Of 93 evaluable episodes, 76 were treated with recombinant, activated FVII (rFVIIa), eight with fresh frozen plasma (FFP), s…

MaleRegistrieTime FactorsFactor VII Deficiency030204 cardiovascular system & hematologyReplacement therapyProspective evaluationchemistry.chemical_compound0302 clinical medicineMedicineProspective StudiesRegistriesYoung adultProspective cohort studyFactor VII deficiencyChildHematologyFactor VIIHematologyMiddle AgedRecombinant ProteinBlood Coagulation FactorsRecombinant ProteinsTreatment OutcomeCoagulantChild PreschoolFemaleBlood Coagulation FactorHumanAdultmedicine.medical_specialtyAdolescentTime FactorHemorrhageBlood Component TransfusionFactor VIIaBleeds; Factor VII deficiency; Replacement therapy; Adolescent; Adult; Aged; Blood Coagulation Factors; Child; Child Preschool; Coagulants; Drug Administration Schedule; Factor VII Deficiency; Factor VIIa; Female; Hemorrhage; Humans; Infant; Infant Newborn; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Registries; Time Factors; Treatment Outcome; Young Adult; Blood Component Transfusion; HematologyDrug Administration Schedule03 medical and health sciencesYoung AdultInternal medicineHumansAgedBleeding episodesbusiness.industryCoagulantsInfant NewbornInfantSurgeryProspective StudieTreatment evaluationchemistryBleedbusiness030215 immunology
researchProduct

Efficacy and safety of Wilate in paediatric VWD patients under 6 years of age - results of a prospective multicentre clinical study including recover…

2013

Treatment with exogenous von Willebrand factor (VWF) is indicated in patients with von Willebrand disease (VWD) in whom treatment with 1-deamino-8-d-arginine vasopressin/desmopressin is contraindicated. Wilate is a new generation plasma-derived concentrate of native VWF and coagulation factor VIII (FVIII) (in a physiological 1:1 ratio) developed for the treatment of VWD. This is the first study to report safety, efficacy and in vivo recovery (IVR) data from 15 paediatric patients less than 6 years of age who received Wilate for either prophylaxis, on-demand treatment or for treatment in surgical procedures during a prospective open-label trial (VWD type 1: 5, type 2A: 1, type 2B: 2, type 3:…

Malecongenital hereditary and neonatal diseases and abnormalitiesPediatricsmedicine.medical_specialtyHemorrhageClinical studyVon Willebrand factorhemic and lymphatic diseasesvon Willebrand FactormedicineVon Willebrand diseaseHumansProspective StudiesChildDesmopressinGenetics (clinical)Paediatric patientsBleeding episodesFactor VIIIbiologyCoagulantsbusiness.industryInfantHematologyGeneral Medicinemedicine.diseasevon Willebrand DiseasesPhenotypeCoagulationTolerabilityChild Preschoolbiology.proteinFemalebusinessHalf-Lifemedicine.drugHaemophilia
researchProduct

Hemorrhage in patients under oral anticoagulation for atrial fibrillation. The other side of the coin

2019

Abstract Introduction and objectives Oral anticoagulation therapy is prescribed to most patients with atrial fibrillation. The main limitation of anticoagulant treatment is the occurrence of bleeding episodes. We sought to assess the type of hemorrhages and mortality in patients anticoagulated for nonvalvular atrial fibrillation. Methods Observational retrospective study analyzing 2 081 138 hospitalization reports from 2014 corresponding to 151 hospitals of the Spanish National Health System. Patients were selected with the diagnosis of hemorrhage, nonvalvular atrial fibrillation, and oral anticoagulation. Results A total of 5783 hospitalizations were analyzed. Most hemorrhages were digesti…

National healthmedicine.medical_specialtyBleeding episodeseducation.field_of_studybusiness.industryPopulationRetrospective cohort studyAtrial fibrillationmedicine.diseaseAnticoagulant therapyInternal medicinemedicineIn patientCardiology and Cardiovascular MedicineeducationbusinessOral anticoagulationREC: CardioClinics
researchProduct

Comparison of physical activity and sedentary behaviours between young haemophilia A patients and healthy adolescents

2011

In recent studies, adolescent haemophilia A patients and healthy adolescents have been encouraged to participate in physical activity (PA) based on its many established health benefits. However, none of the studies to date has used objective measures of PA and sedentary behaviour. The aims of the current study included: (i) to determine the amount and intensity of habitual PA among haemophilia A and healthy adolescents, and in haemophilia A patients with and without bleeding episodes in the previous year, and (ii) to identify the type and determine the time spent in sedentary activities in which both groups participate to obtain a broadened view of their daily activities. A total of 41 adol…

medicine.medical_specialtyBleeding episodesActivities of daily livingbusiness.industryCross-sectional studyHaemophilia ATriaxial accelerometerPhysical activityHematologyGeneral MedicineHealth benefitsmedicine.diseaseHaemophiliamedicinePhysical therapybusinessGenetics (clinical)Haemophilia
researchProduct

The orthopaedic status of severe haemophiliacs in Spain

2000

Summary. This paper provides an outline of the results obtained in a cross-sectional study conducted primarily with the aim of ascertaining orthopaedic complications in a group of young severe A and B haemophiliacs, the effects which these complications have on the medical resources used with these patients, and the impact of severe haemophilia on their quality of life. Its secondary aim was to link their current orthopaedic status to the type of treatment they had received prior to the study. Eleven Spanish hospitals took part in this study, monitoring 70 severe haemophiliacs (FVIII:C 6 months). In 40 cases (57.1%) the patients underwent one or more periods of prophylaxis. Thirty-three pat…

medicine.medical_specialtyBleeding episodesHaemophilic arthropathyPediatricsbusiness.industrySecondary prophylaxisHematologyGeneral MedicineHaemophiliamedicine.diseasemedicine.anatomical_structureQuality of lifeRadiological weaponOrthopedic surgerymedicineAnklebusinessGenetics (clinical)Haemophilia
researchProduct

Joint protection in haemophilia

2011

Haemarthroses (intra-articular haemorrhages) are a frequent finding typically observed in patients with haemophilia. Diagnosis and treatment of these bleeding episodes must be delivered as early as possible. Additionally, treatment should ideally be administered intensively (enhanced on-demand treatment) until the resolution of symptoms. Joint aspiration plays an important role in acute and profuse haemarthroses as the presence of blood in the joint leads to chondrocyte apoptosis and chronic synovitis, which will eventually result in joint degeneration (haemophilic arthropathy). Ultrasonography (US) is an appropriate diagnostic technique to assess the evolution of acute haemarthrosis in hae…

medicine.medical_specialtyBleeding episodesHematologymedicine.diagnostic_testbusiness.industryGold standardMagnetic resonance imagingHematologyGeneral MedicineHemarthrosismedicine.diseaseHaemophiliaSurgeryInternal medicineArthropathymedicineIntensive care medicinebusinessGenetics (clinical)Subclinical infectionHaemophilia
researchProduct